Advanced search
Publication Cover
Personalized Medicine Volume 9, 2012 - Issue 4
Submit an article Journal homepage
97
Views
0
CrossRef citations to date
0
Altmetric
Research Article

CYP2D6*4 Polymorphism, Tramadol Treatment and its Clinical Impact in Patients with Postherpetic Neuralgia

Namita Vilas Nasare1 Department of Pharmacology, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110095, India;2 Environmental Biochemistry & Molecular Biology Laboratory, Department of Biochemistry, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110 095, IndiaView further author information
,
Pravin Suryakantrao Deshmukh2 Environmental Biochemistry & Molecular Biology Laboratory, Department of Biochemistry, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110 095, IndiaView further author information
,
Basu Dev Banerjee2 Environmental Biochemistry & Molecular Biology Laboratory, Department of Biochemistry, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110 095, IndiaCorrespondence[email protected]
View further author information
,
Pramod Kumari Mediratta1 Department of Pharmacology, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110095, IndiaView further author information
,
Rafat S Ahmed2 Environmental Biochemistry & Molecular Biology Laboratory, Department of Biochemistry, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110 095, IndiaView further author information
,
Ashok Kumar Saxena3 Department of Anesthesia, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110095, IndiaView further author information
&
Sambit Nath Bhattacharya4 Department of Dermatology & Venerology, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi-110095, IndiaView further author information
 show all
Pages 371-385 | Published online: 18 Jun 2012

References

  • Wu CL , RajaSN. An update on the treatment of post herpetic neuralgia. J. Pain9 , 519–530 (2008).
  • Baron R , WasnerG. Prevention and treatment of post herpetic neuralgia. Lancet367 , 186–188 (2006).
  • Gilden DH . Herpes zoster with postherpetic neuralgia – persisting pain and frustration. N. Engl. J. Med.330 , 932–934 (1994).
  • Oxman MN , LevinMJ, JohnsonGR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352 , 2271–2284 (2005).
  • Gauthier A , BreuerJ, CarringtonD, MartinM, RémyV. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemol. Infect.137 , 38–47 (2009).
  • Dworkin RH , GnannJ Jr, Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and post herpetic neuralgia. J. Pain37(9) , 1441–1486 (2008).
  • Dworkin RH , PortenoyRK. Pain and its persistence in herpes zoster. Pain67 , 241–251 (1996).
  • Dworkin RH , SchmaderKE, WatsonCPN, GershonAA. The Epidemiology and Natural History of Herpes Zoster and Post Herpetic Neuralgia. Elsevier Press, NY, USA 2 , 39–64 (2001).
  • Raffa RB , FriderichsE. The basic science aspect of tramadol hydrochloride. Pain Rev.3 , 249–271 (1996).
  • Katz J , CooperEM, WaltherRR, SweeneyEW, DworkinRH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin. Infect. Dis.39 , 342–348 (2004).
  • Sindrup SH , JensenTS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain83 , 389–400 (1999).
  • Harati Y , GoochC, SwensonM et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J. Diabetes Compl. 14 , 65–70 (2000).
  • Russell IJ , KaminM, SagerDS. Efficacy of tramadol in treatment of pain in fibromyalgia. Arthritis Rheum.40(Suppl.) , S521 (1997).
  • Raffa RB , FriderichsE. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J. Pharmacol. Exp. Ther.267 , 331–340 (1993).
  • Dayer P , DesmeulesJ, CollartL. Pharmacology of tramadol. Drugs53 , 18–27 (1997).
  • Grond S , SablotzkiA. Clinical pharmacology of tramadol. Clin. Pharmacokinet.43 , 879–923 (2004).
  • Boureau F , LegallicerP, Kabir-AhmadiM. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain104 , 323–333 (2003).
  • Katz N . The impact of pain management on quality of life. J. Pain Sym. Manag.24(1) , 38–47 (2002).
  • Ingelman-Sundberg M . Genetic polymorphism of cytochrome P4502D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. J. Pharmacogenomics5 , 6–13 (2005).
  • Ingelman-Sundberg M , SimSC, GomezA, Rodriguez-AntonaC. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther.116 , 496–526 (2007).
  • Nageswararao D , ManjulaG, SailajaK et al. Association of CYP2D6*4 polymorphism with acute leukemia. J. Cell Tissue Res. 10(2) , 2201–2205 (2010).
  • Kirchheiner J , KeulenJT, BauerS, RootsI, BrockmöllerJ. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol.28 , 78–83 (2008).
  • Dahl ML , BertilssonL. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics3 , 61–70 (1993).
  • Ismail R , TehLK. Genetic polymorphism of CYP2D6: Malaysian Indians have the highest frequency for CYP2D6*4 in Asia. Eur. J. Clin. Pharmacol.57 , 617–618 (2001).
  • Ismail R . CYP2D6 genotype and phenotype relationship in south Indians. J. Postgrad. Med.52(4) , 245 (2006).
  • Naveen AT , PrasannaT, FarzanaBL, RajanS, AdithanC. CYP2D6 genotype and phenotype relationship in South Indians. J. Postgrad. Med.52(4) , 253–256 (2006).
  • Hartrick CT , KovanJP, ShapiroS. The numeric rating scale for clinical pain measurement: a ratio measure? Pain Pract.3(4) , 310–316 (2003).
  • Bouhassira D , AttalN, FermanianJ et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108(3) , 248–257 (2004).
  • Paro HB , MoralesNM, SilvaCH et al. Health-related quality of life of medical students. Med. Educ. 44 , 227–235 (2010).
  • Harati Y , GoochC, SwensonM et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50(6) , 1842–1846 (1998).
  • Gan HG , RusliI, WanA, WanZ. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol. Diagn. Ther.11(3) , 171–181 (2007).
  • Volpi A , GattiA, SerafiniG et al. Clinical and psychosocial correlates of acute pain in herpes zoster. J. Med. Virol. 38 , 275–279 (2007).
  • Meister W , NeissA, GrossG, DoerrHW, HobelW, MalinJP. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection26 , 359–363 (1998).
  • Jung BF , JohnsonRW, GriffinDR, DworkinRH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology62(9) , 1545–1551 (2004).
  • Volpi A , GattiA, PicaF, BellinoS, MarsellaLT, SabatAF. Clinical and psychosocial correlates of post-herpetic neuralgia. J. Med. Virol.80(9) , 1646–1652 (2008).
  • Parruti G , TontodonatiM, RebuzzC et al. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy. BMC Med. 8 , 58 (2010).
  • Coen PG , ScottF, Leedham-GreenM et al. Predicting and preventing post-herpetic neuralgia: are current risk factors useful in clinical practice? Eur. J. Pain 10 , 695–700 (2006).
  • Gauthier A , BreuerJ, CarringtonD, MartinM, RémyV. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol. Infect9 , 1–10 (2008).
  • Chidiac C , BrucelleJ, DauresJP et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin. Infect. Dis. 33 , 62–69 (2001).
  • Fleming DM , CrossKW, CobbWA, ChapmanRS. Gender difference in the incidence of shingles. Epidemiol. Infect.132 , 1–5 (2004).
  • Opstelten W , Van Essen GA, Schellevis F, Verheij TJ, Moons KG. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann. Epidemiol.16 , 692–695 (2006).
  • Schmader K , GorgeLK, BurchettBM, PieperCF, HamiltonJD. Racial differences in the occurrence of herpes zoster. J. Infect. Dis.171 , 701–704 (1995).
  • Concato J , PeduzziP, HolfordTR, FeinsteinAR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J. Clin. Epidemiology48 , 1495–1501 (1995).
  • Choo PW , GalilK, DonahueJG, WalkerAM, SpiegelmanD, PlattR. Risk factors for postherpetic neuralgia. Arch. Intern. Med.157 , 1217–1224 (1997).
  • Decroix J , PartschH, GonzalesR et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. Valaciclovir International Zoster Assessment Group (VIZA). J. Eur. Acad. Dermatol. Venereol. 14 , 23–33 (2000).
  • Scott FT , Leedham-GreenME, Barrett-MuirWY et al. A study of shingles and the development of postherpetic neuralgia in east London. J. Med. Virol. 70 , S24–S30 (2003).
  • Volpi A , GattiA, PicaF, BellinoS, MarsellaLT, SabatAF. Clinical and psychosocial correlates of post-herpetic neuralgia. J. Med. Virol.80(9) , 1646–1652 (2008).
  • Drolet M , BrissonM, SchmaderKE et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 182(16) , 1731–6 (2010).
  • Concise Medical Dictionary. 3rd Edition. Oxford University Press, Oxford, UK (1990).
  • Cruccu G , SommerC, AnandP et al. EFNS guidelines on neuropathic pain assessment revised. Eur. J. Neurol. 10 , 1468–1331 (2010).
  • Mogil JS , GriselJE. Transgenic studies of pain. Pain77 , 107–128 (1998).
  • Uhl GR , SoraI, WangZJ. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc. Natl Acad. Sci.96 , 7752–7755 (1999).
  • Meyer UA , ZangerUM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol.37 , 269–296 (1997).
  • Jaanson P , MarandiT, KiivetRA, VasarV, VäänS, SvenssonJ. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl.)162 , 67–73 (2002).
  • Hamelin BA , DorsonPG, PabisD et al. CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy19 , 1057–1063 (1999).
  • Dworkin RH , CorbinAE, YoungJP Jr et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology60 , 1274–1283 (2003).
  • Attal N , CruccuG, HaanpääM et al.; EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol.13 , 1153–1169 (2006).
  • Jensen MK , ThomsenAB, H⊘jstedJ. 10-year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur. J. Pain10 , 423–433 (2006).
  • Jensen MP , ChiangYK, WuJ. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clin. J. Pain25 , 286–292 (2009).
  • Ranoux D , AttalN, MorainF, BouhassiraD. Botulinum toxin a induces direct analgesic effects in neuropathic pain: a double blind placebo controlled study. Ann. Neurol.64 , 274–283 (2008).
  • Edwards RR , HaythornthwaiteJA, TellaP, MaxMB, RajaS. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology104 , 1243–1248 (2006).
  • Wasner G , KleinertA, BinderA, SchattschneiderJ, BaronR. Postherpetic neuralgia: topical lidocaine is effective in nociceptor deprived skin. J. Neurol.252 , 677–686 (2005).
  • Albert JM , WijckMD, WallaceM et al. Herpes zoster and post-herpetic neuralgia. Pain Practice 11(1) , 88–97 (2011).
  • Chidiac C , BruxelleJ, DauresJP et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin. Infect. Dis. 33 , 62–69 (2001).
  • Schmader KE , SloaneR, PieperC et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin. J. Pain 23 , 490–496 (2007).
  • Oster G , HardingG, DukesE, EdelsbergJ, ClearyPD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J. Pain6 , 356–363 (2005).
  • Johnson RJ , McElhaneyJ. Post-herpetic neuralgia in the elderly. Int. J. Clin. Pract.63 , 1386–1391 (2009).
  • Lehmann KA , KratzenbergU, Schroeder-BarkB et al. Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimus meffective concentration. J. Clin. Pain 6 , 212–220 (1990).
  • Follin SL , CharlandSL. Actute pain management: operative or medical procedures and trauma. Ann. Pharmacol.31(9) , 1068–1076 (1997).
  • Panagiotidis G , ArthurHW, LindhJD, DahlML, SjöqvistF. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther. Drug Monit.27 , 417–422 (2007).
  • Blonk MI , van der Velde N, van den Bemt PM, van Schaik RH, van der Cammen TJ. CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people. Pharm. World Sci.2(1) , 26–29 (2010).
  • Tiwari AK , DeshpandeSN, RaoAR et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schiz. Res. 75 , 21–26 (2005).
  • Rau T , WohllobanG, WuttkeH et al. CYP2D6 genotype: impact on adverse effects and non response during treatment with antidepressants: a pilot study. J. Clin. Pharmacol. Ther.75(5) , 386–393 (2004).
  • Stamer U , StuberF, MudersT, MusshoffF. Respiratory depression with tramadol in patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg.107 , 926–929 (2008).
  • Lotsch J , SkarkeC, LiefhildJ et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future prospective. Clin. Pharmacokinet. 43 , 98–1013 (2004).
  • Eckhardt K , AmmonS. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain76(1–2) , 27–33 (1998).
  • Caraco Y , ShellerJ, WoodAJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J. Pharmacol. Exp. Ther.278 , 1165–1174 (1996).
  • Otton SV , WuD, JoffeRT. Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin. Pharmacol. Ther.53(4) , 401–409 (1993).
  • Heiskanen K , KalsoE. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin. Pharmacol. Ther.64 , 603–611 (1998).
  • Enggard TP , PoulsenL. The analgesic effect of tramadol after intravenoud injection in healty volunteers in relation to CYP2D6. Anesth. Analg.102 , 146–150 (2006).
  • Stamer UM , LehnenK, HöthkerF et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105 , 231–238 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.